CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization

Journal of General Virology

Volumn 89, Issue 12, 2008, Pages 2954-2964

  Sundling, Christopher ^a,b   Schön, Karin ^c   Mörner, Andreas ^a   Forsell, Mattias N E ^b,d   Wyatt, Richard T ^d   Thorstensson, Rigmor ^a   Karlsson Hedestam, Gunilla B ^a,b   Lycke, Nils Y ^c  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; VIRUS ENVELOPE PROTEIN; CHOLERA TOXIN; CTA1 DD PROTEIN, RECOMBINANT; CTA1-DD PROTEIN, RECOMBINANT; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; LUNG LAVAGE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; VAGINA SECRETION; VIRUS IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MACACA; MALE; T LYMPHOCYTE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; PRIMATES;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; CHOLERA TOXIN; FEMALE; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 58149401439     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.2008/005470-0     Document Type: Article

References (75)

1. Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K. & Akira, S. (1998). Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9, 143-150.
2. Agren, L. C., Ekman, L., Lowenadler, B. & Lycke, N. Y. (1997). Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 158, 3936-3946.
3. Akhiani, A. A., Pappo, J., Kabok, Z., Schon, K., Gao, W., Franzen, L. E. & Lycke, N. (2002). Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 169, 6977-6984.
4. Akhiani, A. A., Stensson, A., Schon, K. & Lycke, N. (2006). The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Scand J Immunol 63, 97-105.
5. Albrecht, H. (2003). Making sense of AIDSVAX. AIDS Clin Care 15, 42.
6. Andersen, C. S., Dietrich, J., Agger, E. M., Lycke, N. Y., Lovgren, K. & Andersen, P. (2007). The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun 75, 408-416.
7. Baldridge, J. R., McGowan, P., Evans, J. T., Cluff, C., Mossman, S., Johnson, D. & Persing, D. (2004). Taking a Toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 4, 1129-1138.
8. Barnett, S. W., Lu, S., Srivastava, I., Cherpelis, S., Gettie, A., Blanchard, J., Wang, S., Mboudjeka, I., Leung, L. & other authors (2001). The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75, 5526-5540.
9. Barnett, S. W., Srivastava, I. K., Kan, E., Zhou, F., Goodsell, A., Cristillo, A. D., Ferrai, M. G., Weiss, D. E., Letvin, N. L. & other authors (2008). Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22, 339-348.
10. Barton, G. M. & Medzhitov, R. (2002). Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol 14, 380-383.
11. Bergmeier, L. A. & Lehner, T. (2006). Innate and adaptive mucosal immunity in protection against HIV infection. Adv Dent Res 19, 21-28.
12. Beutler, B. (2007). Neo-ligands for innate immune receptors and the etiology of sterile inflammatory disease. Immunol Rev 220, 113-128.
13. Binley, J. M., Sanders, R. W., Clas, B., Schuelke, N., Master, A., Guo, Y., Kajumo, F., Anselma, D. J., Maddon, P. J. & other authors (2000). A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74, 627-643.
14. Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J., Sodroski, J., Wilson, I. A. & Wyatt, R. T. (2004). HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5, 233-236.
15. Burton, D. R., Stanfield, R. L. & Wilson, I. A. (2005). Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 102, 14943-14948.
16. Choi, A. H., McNeal, M. M., Flint, J. A., Basu, M., Lycke, N. Y., Clements, J. D., Bean, J. A., Davis, H. L., McCluskie, M. J. & other authors (2002). The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine 20, 1733-1740.
17. De Filette, M., Ramne, A., Birkett, A., Lycke, N., Lowenadler, B., Min Jou, W., Saelens, X. & Fiers, W. (2006). The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24, 544-551.
18. SF162P4 and heterologous HIV-1 infection. J Virol 80, 8745-8762.
19. Dickinson, B. L. & Clements, J. D. (1995). Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 63, 1617-1623.
20. Eliasson, D. G., Bakkouri, K. E., Schon, K., Ramne, A., Festjens, E., Lowenadler, B., Fiers, W., Saelens, X. & Lycke, N. (2008). CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26, 1243-1252.
21. Eriksson, A. M., Schon, K. M. & Lycke, N. Y. (2004). The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 173, 3310-3319.
22. Forsell, M. N., McInerney, G. M., Dosenovic, P., Hidmark, A. S., Eriksson, C., Liljestrom, P., Grundner, C. & Karlsson Hedestam, G. B. (2007). Increased human immunodeficiency virus type 1 Env expression and antibody induction using an enhanced alphavirus vector. J Gen Virol 88, 2774-2779.
23. Gavin, A. L., Hoebe, K., Duong, B., Ota, T., Martin, C., Beutler, B. & Nemazee, D. (2006). Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314, 1936-1938.
24. Girard, M. P., Bansal, G. P., Pedroza-Martins, L., Dodet, B., Mehra, V., Schito, M., Mathieson, B., Delfraissy, J. F. & Bradac, J. (2008). Mucosal immunity and HIV/AIDS vaccines Report of an International Workshop, 28-30 October 2007. Vaccine 26, 3969-3977.
25. Grdic, D., Ekman, L., Schon, K., Lindgren, K., Mattsson, J., Magnusson, K. E., Ricciardi-Castagnoli, P. & Lycke, N. (2005). Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxin. J Immunol 175, 5192-5202.
26. Grundner, C., Pancera, M., Kang, J. M., Koch, M., Sodroski, J. & Wyatt, R. (2004). Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology 330, 233-248.
27. Gupta, K. & Klasse, P. J. (2006). How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? PLoS Med 3, e79.
28. Guy, B. (2007). The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5, 505-517.
29. Haase, A. T. (2005). Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5, 783-792.
30. Harris, G., KuoLee, R. & Chen, W. (2006). Role of Toll-like receptors in health and diseases of gastrointestinal tract. World J Gastroenterol 12, 2149-2160.
31. Haynes, B. F. & Shattock, R. J. (2008). Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol 122, 3-9.
32. Hemmi, H., Kaisho, T., Takeda, K. & Akira, S. (2003). The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 170, 3059-3064.
33. Hladik, F. & McElrath, M. J. (2008). Setting the stage: host invasion by HIV. Nat Rev Immunol 8, 447-457.
34. Hol, W. G. J., Sixma, T. K. & Merritt E. A. (1995). Structure and function of E. coli heat-labile enterotoxin and cholera toxin B pentamer. In Natural Toxins: Bacterial Toxins and Virulence Factors in Disease, pp. 185-223. Edited by J. Moss, M. Vaughan, B. Iglewski & A. T. Tu. New York: Marcel Dekker, Inc.
35. Karlsson Hedestam, G. B., Fouchier, R. A., Phogat, S., Burton, D. R., Sodroski, J. & Wyatt, R. T. (2008). The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6, 143-155.
36. Kim, M., Giao, Z S., Montefiori, D. C., Haynes, B. F., Reinherz, E. L. & Liao, H. X. (2005). Comparison of HIV type 1 ADA gp120 monomers versus gp, 140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res Hum Retroviruses 21, 58-67.
37. Kozlowski, P. A. & Neutra, M. R. (2003). The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 3, 217-228.
38. Kwissa, M., Kasturi, S. P. & Pulendran, B. (2007). The science of adjuvants. Expert Rev Vaccines 6, 673-684.
39. Lavelle, E. C., Jarnicki, A., McNeela, E, Armstrong, M. E., Higgins, S. C., Leavy, O. & Mills, K H. (2004). Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J Leukoc Biol 75, 756-763.
40. Levine, M. M. & Sztein, M. B. (2004). Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 5, 460-464.
41. Li, Y., Svehla, K., Mathy, N. L., Voss, G., Mascola, J. R. & Wyatt, R. (2006). Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 80, 1414-1426.
42. Liang, S., Wang, M., Triantafilou, K,, Triantafilou, M., Nawar, H. F., Russell, M. W., Connell, T. D. & Hajishengallis, G. (2007). The A subunit of type IIb, enterotoxin (LT-IIb) suppresses the proinflammatory potential of the B subunit and its ability to recruit and interact with TLR2. J Immunol 178, 4811-4819.
43. Lycke, N. (2007). Mechanisms of Adjuvant Action. In Vaccine Adjuvants and Delivery Systems, pp. 53-79. Edited by M. Singh. Hoboken, NJ: John Wiley & Sons.
44. Maher, D., Wu, X., Schacker, T., Horbul, J. & Southern, P. (2005). HIV binding, penetration, and primary infection in human cervicovaginal tissue. Proc Natl Acad Sci U S A 102, 11504-11509.
45. + T-cell-mediated immunity against genital tract Chlamydia trachomatis infection. Infect Immun 75, 4638-4647.
46. Mascola, J. R. (2003). Defining the protective antibody response for HIV-1. Curr Mol Med 3, 209-216.
47. Mazanec, M. B., Kaetzel, C. S., Lamm, M. E., Fletcher, D. & Nedrud, J. G. (1992). Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A 89, 6901-6905.
48. Mazzoll, S., Trabattoni, D., Lo Caputo, S., Piconi, S., Ble, C., Meacci, F., Ruzzante, S., Salvi, A., Semplici, F. & other authors (1997). HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 3, 1250-1257.
49. McGettrick, A. F. & O'Neill, L. A. (2007). Toll-like receptors: key activators of leucocytes and regulator of haernatopoiesis. Br J Haematol 139, 185-193.
50. McNeal, M. M., Basu, M, Bean, J. A., Clements, J. D., Lycke, N. Y., Ramne, A., Lowenadler, B., Choi, A. H. & Ward, R. L. (2007). Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge. Vaccine 25, 6224-6231.
51. Mestecky, J., Moldoveanu, Z. & Russell, M. W. (2005). Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol 53, 208-214.
52. Montefiori, D., Sattentau, Q., Flores, J., Esparza, J. & Mascola, J. (2007). Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 4, e348.
53. Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C. & Steffen, R. (2004). Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350, 896-903.
54. Neutra, M. R. & Kozlowski, P. A. (2006). Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6, 148-158.
55. Parren, P. W., Marx, P. A., Hassell, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P. & Burton, D. R. (2001). Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/ human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75, 8340-8347.
56. Pasare, C. & Medzhitov, R. (2005). Control of B-cell responses by Toll-like receptors. Nature 438, 364-368.
57. Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., Hu, D., Tappero, J. W. & Choopanya, K. (2006). Randomized, double-blind, placebo - controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194, 1661-1671.
58. Sanders, R. W., Vesanen, M., Schuelke, N., Master, X., Schiffner, L., Kalyanaraman, R., Paluch, M., Berkhout, B., Maddon, P. J. & other authors (2002). Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76, 8875-8889.
59. Shattock, R. J., Haynes, B. F., Pulendran, B., Flores, J. & Esparza, J. (2008). Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med 5, e81.
60. Simmons, C. P., Mastroeni, P., Fowler, R., Ghaem-maghami, M., Lycke, N., Pizza, M., Rappuoll, R. & Dougan, G. (1999). MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol 163, 6502-6510.
61. Sin, J. I., Kim, J. J., Boyer, J. D., Ciccarelli, R. B., Higgins, T. J. & Weiner, D. B. (1999). In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol 73, 501-509.
62. Srivastava, I. K., VanDorsten, K., Vojtech, L., Barnett, S. W. & Stamatatos, L. (2003). Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 77, 2310-2320.
63. Stephenson, I., Zambon, M. C., Rudin, A., Colegate, A., Podda, A., Bugarini, R., Del Giudice, G., Minutello, A., Bonnington, S. & other authors (2006). Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80, 4962-4970.
64. Tritto, E., Muzzi, A., Pesce, I., Monaci, E., Nuti, S., Galli, G., Wack, A., Rappuoli, R., Hussell, T. & De Gregorio, E. (2007). The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature. J Immunol 179, 5346-5357.
65. Underhill, D. M. & Ozinsky, A. (2002). Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 14, 103-110.
66. Vajdy, M., Singh, M., Kazzaz, J., Soenawan, E., Ugozzoli, M., Zhou, F., Srivastava, I., Bin, Q., Barnett, S. & other authors (2004). Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retroviruses 20, 1269-1281.
67. Veazey, R. S., Shattock, R. J., Pope, M., Kirijan, J. C., Jones, J., Hu, Q., Ketas, T., Marx, P. A., Klasse, P. J. & other authors (2003). Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1- gp120. Nat Med 9, 343-346.
68. Vogel, F. R. (1995). Immunologic adjuvants for modern vaccine formulations. Ann N Y Acad Sci 754, 153-160.
69. Wicker, S., Rabenau, H. F., Gottschalk, R., Doerr, H. W. & Allwinn, R. (2007). Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students. Med Microbiol Immunol 196, 145-150.
70. Xu, R., Srivastava, I. K, Greer, C. E., Zarkikh, I., Kraft, Z., Kuller, L., Polo, J. M., Barnett, S. W. & Stamatatos, L. (2006a). Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res Hum Retroviruses 22, 1022-1030.
71. Xu, R., Srivastava, I. K., Kuller, L., Zarkikh, I., Kraft Z., Fagrouch, Z., Letvin, N. L., Heaney, J. L., Barnett, S. W. & Stamatatos, L. (2006b). Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology 349, 276-289.
72. Yang, X., Flori L., Farzan, M., Kolchinsky, P., Kwong, P. D., Sodroski, J. & Wyatt, R. (2000). Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J Virol 74, 4746-4754.
73. Yang, X., Wyatt, R. & Sodroski, J. (2001). Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 75, 1165-1171.
74. Yang, X., Lee, J., Mahony, E. M., Kwong, P. D., Wyatt, R. & Sodroski, J. (2002). Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 76, 4634-4642.
75. Zignol, M., Peracchi, M., Tridello, G., Pillon, M., Fregonese, F., D'Elia, R., Zanesco, L. & Cesaro, S. (2004). Assessment of Immoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 101, 635-641.